Clearside Biomedical (NASDAQ:CLSD – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.03, Zacks reports. The company had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.27 million.
Clearside Biomedical Trading Down 7.8 %
Shares of CLSD stock opened at $0.95 on Friday. The firm has a market capitalization of $72.05 million, a P/E ratio of -2.11 and a beta of 2.10. Clearside Biomedical has a 1 year low of $0.77 and a 1 year high of $1.65. The firm’s fifty day simple moving average is $0.96 and its 200 day simple moving average is $1.05.
Analysts Set New Price Targets
A number of equities analysts have recently commented on CLSD shares. Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Clearside Biomedical in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Clearside Biomedical in a research note on Thursday, March 6th. StockNews.com downgraded shares of Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Tuesday, March 18th. Finally, Needham & Company LLC decreased their price target on shares of Clearside Biomedical from $6.00 to $4.00 and set a “buy” rating for the company in a report on Friday. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $5.25.
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Further Reading
- Five stocks we like better than Clearside Biomedical
- CD Calculator: Certificate of Deposit Calculator
- MarketBeat Week in Review – 03/24 – 03/28
- What is a Stock Market Index and How Do You Use Them?
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- How to find penny stocks to invest and trade
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
